Skip to content

Study · In silico · 2023

9 results

Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.

Kan M, Fu H, Xu Y, Yue Z, Du B, Chen Q, Wang X, Yu S, Zhang Z

Diabetes, obesity & metabolism2 Aug 2023Cited by 5 (Europe PMC)

PMID37529870 (opens in a new tab)DOI10.1111/dom.15219 (opens in a new tab)PepBankPUB-37529870
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01Computer modelIn silicoMechanism

    Network pharmacology enriched two key targets of semaglutide in type 2 diabetes with coronary artery disease.

    In plain wordsA computer analysis predicted two key targets for semaglutide in a model of diabetes with heart artery disease; this is a prediction only.

    Peptide
    Semaglutide
    Outcome
    Not applicablePredicted key targets of semaglutide
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    two key targets of semaglutide were enriched.

Studies that did not test the peptide alone8

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled dulaglutide, exenatide and semaglutide reduced the incidence of non-fatal stroke versus placebo.

    In plain wordsIn adults with type 2 diabetes, three weekly GLP-1 drugs pooled together lowered non-fatal stroke compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseNon-fatal stroke
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    The pooled analysis found that dulaglutide, exenatide and semaglutide outperformed placebo in cardiovascular outcomes in patients with T2DM, with a significant reduction in the incidence of non-fatal stroke (p < .00).
    1 context sentence
    Summary · context
    In total, 13 studies with 35 563 participants were included in the analysis.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes and coronary artery disease, pooled once-weekly GLP-1 receptor agonists reduced glycated haemoglobin versus conventional treatment.

    In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled weekly GLP-1 drugs lowered HbA1c compared with conventional treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycated haemoglobin
    Study

    n: not reported in source

    Comparator
    Conventional treatment
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    glycated haemoglobin: p < .00
    1 context sentence
    Summary · context
    In total, 13 studies with 35 563 participants were included in the analysis.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes and coronary artery disease, pooled once-weekly GLP-1 receptor agonists reduced fasting blood glucose versus conventional treatment.

    In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled weekly GLP-1 drugs lowered fasting blood sugar compared with conventional treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting blood glucose
    Study

    n: not reported in source

    Comparator
    Conventional treatment
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    fasting blood glucose: p < .00
    1 context sentence
    Summary · context
    In total, 13 studies with 35 563 participants were included in the analysis.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes and coronary artery disease, pooled once-weekly GLP-1 receptor agonists reduced weight versus conventional treatment.

    In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled weekly GLP-1 drugs lowered weight compared with conventional treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight
    Study

    n: not reported in source

    Comparator
    Conventional treatment
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    weight: p < .00
    1 context sentence
    Summary · context
    In total, 13 studies with 35 563 participants were included in the analysis.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes and coronary artery disease, pooled once-weekly GLP-1 receptor agonists reduced systolic blood pressure versus conventional treatment.

    In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled weekly GLP-1 drugs lowered systolic blood pressure compared with conventional treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Comparator
    Conventional treatment
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    systolic blood pressure: p < .00
    1 context sentence
    Summary · context
    In total, 13 studies with 35 563 participants were included in the analysis.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes and coronary artery disease, pooled once-weekly GLP-1 receptor agonists reduced total cholesterol versus conventional treatment.

    In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled weekly GLP-1 drugs lowered total cholesterol compared with conventional treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal cholesterol
    Study

    n: not reported in source

    Comparator
    Conventional treatment
    Outcome group
    Lipids · Cardiovascular

    Source sentences

    Summary
    total cholesterol: p < .00
    1 context sentence
    Summary · context
    In total, 13 studies with 35 563 participants were included in the analysis.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes and coronary artery disease, pooled once-weekly GLP-1 receptor agonists reduced LDL cholesterol versus conventional treatment.

    In plain wordsIn adults with type 2 diabetes and heart artery disease, pooled weekly GLP-1 drugs lowered LDL cholesterol compared with conventional treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL cholesterol
    Study

    n: not reported in source

    Comparator
    Conventional treatment
    Outcome group
    Lipids · Cardiovascular

    Source sentences

    Summary
    low-density lipoprotein cholesterol: p < .00
    1 context sentence
    Summary · context
    In total, 13 studies with 35 563 participants were included in the analysis.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 09Computer modelNot a test of Semaglutide aloneIn silicoMechanism

    Network pharmacology for pooled once-weekly GLP-1 receptor agonists enriched the renin-angiotensin system, with matrix metalloproteinase 2 and renin as possible key targets.

    In plain wordsA computer analysis of pooled weekly GLP-1 drugs linked them to the renin-angiotensin system; this is a prediction, not a measured effect.

    Peptide
    Semaglutide
    Outcome
    Not applicableNetwork pharmacology enrichment of the renin-angiotensin system
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    Network pharmacology results were enriched to the renin-angiotensin system, and matrix metalloproteinase 2 and renin (REN) may be the key targets.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    11 Oct 2026, 00:50 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.